Ragde H, Grado G L, Nadir B, Elgamal A A
Prostate Brachytherapy at Southwest Oncology Center, Scottsdale, AZ, USA.
CA Cancer J Clin. 2000 Nov-Dec;50(6):380-93. doi: 10.3322/canjclin.50.6.380.
Of all the treatment options available for men with organ-confined prostate cancer, brachytherapy--permament implantation of radioactive seeds into the prostate gland--is the least disruptive for the patient, both physiologically and practically. Early brachytherapy represents the oldest technique for delivering radiation to the prostate gland, preceding external beam therapy of the prostate by several decades. Although there have not been, and are not likely to be, any definitive randomized studies comparing radical prostatectomy, external beam radiotherapy, and brachytherapy, treatment decisions will continue to be made on the basis of patient and physician preferences in conjunction with clinical probabilities. Long-term results in this series show that monotherapy with seed implants achieved disease-free survival of 66%; moreover, 79% of patients with higher grade disease who were treated with a combination of brachytherapy and external beam radiation also experienced long-term disease-free survival. The following article provides a brief historical review of prostate brachytherapy, rationale for treatments, patient selection criteria, up-to-date implant techniques, and long-term (12-year) outcome results.
对于患有器官局限性前列腺癌的男性而言，在所有可用的治疗方案中，近距离放射疗法——将放射性种子永久植入前列腺——在生理和实际层面上对患者的干扰最小。早期近距离放射疗法是向前列腺输送辐射的最古老技术，比前列腺外照射疗法早几十年。尽管目前尚无且不太可能有任何明确的随机研究来比较根治性前列腺切除术、外照射放疗和近距离放射疗法，但治疗决策仍将基于患者和医生的偏好以及临床概率来做出。本系列的长期结果表明，单纯种子植入疗法实现了66%的无病生存率；此外，79%接受近距离放射疗法和外照射放疗联合治疗的高分级疾病患者也实现了长期无病生存。以下文章简要回顾了前列腺近距离放射疗法的历史、治疗原理、患者选择标准、最新的植入技术以及长期（12年）结果。
